Reading this on a mobile device? Try our optimized mobile version here:

January 23, 2013
Sign upForwardArchive
News for the PBM Industry

  Featured Story 
  • State pharmacy boards overreach in regulating PBMs, compounders
    State pharmacy boards, whose members include pharmacists, have an inherent conflict of interest in regulating and overseeing the thousands of pharmacies nationwide that combine, mix or alter prescription drugs, health care attorney William G. Schiffbauer writes. Pharmacy boards have further overreached their role of self-regulating pharmacists in claiming authority to regulate pharmacy benefit managers, with whom they are often in competition, Schiffbauer adds. State pharmacy boards' authority should be limited to regulating the behavior and competence of pharmacists, finding and disciplining problem pharmacists and handling conflicts of interest in the pharmacy profession, Schiffbauer writes. Bloomberg BNA (subscription required)/Pharmaceutical Law & Industry Report (1/18) LinkedInFacebookTwitterEmail this Story
 Registration is now open for PCMA's Managed Markets Educational Forum!
Whether you are a seasoned managed markets executive or someone who supports the team, PCMA's Managed Markets Educational Forum will provide valuable education on fundamental, as well as complex and strategic issues relevant to professionals of all levels within pharma managed markets or market access divisions. Visit PCMA's website to learn more about our 2013 events!

  Legislative & Regulatory News 
  • Former senator takes the reins at NAIC
    Former Sen. Ben Nelson, D-Neb., will assume the role of CEO at the National Association of Insurance Commissioners. Nelson previously served as executive vice president and chief of staff of the NAIC, directed the Nebraska Department of Insurance and served two terms as governor of Nebraska. Politico (Washington, D.C.) (1/23), Bloomberg (1/22) LinkedInFacebookTwitterEmail this Story
  PBM Industry News 
  Drug Industry Spotlight 
  • Lupin gets FDA approval for generic Lutera
    Lupin Pharmaceuticals received federal approval for its levonorgestrel and ethinyl estradiol contraceptive tablets in the 0.1 mg/0.02 mg strength. The drug is a generic formulation of Lutera, made by Watson Labs. Drug Store News (1/22) LinkedInFacebookTwitterEmail this Story
Lend yourself to others, but give yourself to yourself."
--Michel de Montaigne,
French writer


Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Contact PCMA
Charles Cote
Assistant Vice President, Strategic Communications
(202) 207-3610

Twitter  Follow PCMA on Twitter
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

 Recent PCMA SmartBrief Issues:   Lead Editor:  Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information